

Sphingolipid metabolism in the pathophysiology and treatment of Alzheimer's disease

Citation for published version (APA):

Crivelli, S. (2019). *Sphingolipid metabolism in the pathophysiology and treatment of Alzheimer's disease*. Gildeprint Drukkerijen. <https://doi.org/10.26481/dis.20191114sc>

Document status and date:

Published: 14/11/2019

DOI:

[10.26481/dis.20191114sc](https://doi.org/10.26481/dis.20191114sc)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Statements

1. “The glia have developed numerous fibres; further, many glia include adipose inclusions”. (Alois Alzheimer)
2. There is an increasing body of evidence linking sphingolipid metabolism to Alzheimer’s disease pathophysiology: ceramide levels are elevated.
3. Notably, multiple studies of different populations and methodologies suggest that elevated blood ceramides are associated with an increased risk of Alzheimer’s disease and progression of cognitive decline. (Michelle Mielke)
4. Ceramide transport from the endoplasmic reticulum to the *trans*-Golgi apparatus plays a key role in ceramide accumulation in the brain of Alzheimer’s disease mouse models. (*in this thesis*)
5. Ceramide transfer protein overexpression in the brain reduces inflammation in a mouse model of Alzheimer’s disease. (*in this thesis*)
6. Ceramide analogs, like HPA-12, have a higher brain uptake in mice with Alzheimer’ disease compared to healthy mice. (*in this thesis*)
7. Counteracting ceramide elevation in the brain by administering protective sphingolipid molecules like sphingosine analogs prevents memory impairment and anxiety-like behavior in an Alzheimer’s disease mouse model. (*in this thesis*)
8. The final results appear almost simple [...]; but the years of searching in the dark for a truth that one feels, but cannot express; the intense effort and the alternations of confidence and misgiving, until one breaks through to clarity and understanding, are only known to him who has himself experienced them. (Albert Einstein)
9. Organic chemistry is the child of medicine, and however far it may go on its way, with its most important achievements, it always returns to its parent. (Ludwig Thudichum)
10. One thing only I know, and that is that I know nothing. (Socrates)